Stocktoria
Celldex Therapeutics, Inc. CLDX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1986-05-15
Celldex Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -18599.8% | -2778.9% | -2245.3% | -4889.0% | -1531.8% | -854.1% | -1540.2% | -1640.1% | -953.7% | -1958.7% |
| Net margin | -16748.0% | -2248.8% | -2054.8% | — | — | — | — | — | — | — |
| FCF margin | -13829.1% | -2274.9% | -1585.2% | -4478.6% | -1336.4% | -565.6% | -1319.5% | -797.3% | -798.2% | -1706.3% |
| Return on assets | -44.4% | -19.9% | -30.4% | — | — | — | — | — | — | — |
| Return on equity | -49.1% | -21.1% | -33.0% | — | — | — | — | — | — | — |
| Current ratio | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
Source: SEC EDGAR filings · CIK 0000744218 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.